Understand the source comparison
Wolverine Stack Research Protocols: Compound Comparison
GHRP-2 Ghrelin receptor agonist (GHS-R1a); stimulates pulsatile GH release from anterior pituitary ~30 minutes plasma; GH elevation lasts 2–3 hours 100–300 mcg per administration, 1–2× daily 28 days in bacteriostatic water; potency loss 3–5% per week after day
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-2
- Ghrelin receptor agonist (GHS-R1a); stimulates pulsatile GH release from anterior pituitary
- ~30 minutes plasma; GH elevation lasts 2–3 hours
- 100–300 mcg per administration, 1–2× daily
- 28 days in bacteriostatic water; potency loss 3–5% per week after day 28
- Ideal for acute GH response studies; requires twice-daily dosing for sustained effect; receptor desensitisation risk with >2 doses/day
- GHRP-6
- Ghrelin mimetic; GH secretion + appetite stimulation via hypothalamic signalling
- ~30 minutes plasma; GH peak at 30–60 min
- 100–300 mcg per administration, 1–3× daily
- 28 days in bacteriostatic water; similar stability to GHRP-2
- Stronger appetite effect than GHRP-2; better for studies examining GH-ghrelin-appetite axis; less selective than ipamorelin
- Ipamorelin
- Selective GHS-R1a agonist; GH release without cortisol or prolactin elevation
- ~2 hours (longer than GHRP-2/6)
- 200–300 mcg per administration, 1–2× daily
- 28 days in bacteriostatic water; stable for 35+ days due to higher synthesis purity
- Best selectivity profile; minimal off-target effects; preferred for long-term studies where cortisol/prolactin confounds must be avoided
- BPC-157
- Promotes angiogenesis via VEGF upregulation; modulates growth factor receptor expression
- 4–6 hours (tissue-dependent)
- 250–500 mcg per administration, 1× daily
- 14–21 days in bacteriostatic water; degrades faster than GHRPs due to peptide bond instability
- Strongest evidence for tendon/ligament repair; works synergistically with GH secretagogues; dose timing matters more than dose size
- TB-500 (Thymosin Beta-4 fragment)
- Actin-binding peptide; promotes cell migration and differentiation in damaged tissue
- ~2–3 hours in circulation; tissue retention up to 7 days
- 2–5 mg per administration, 1–2× weekly
- 28 days in bacteriostatic water; relatively stable but light-sensitive
- Longer dosing interval than BPC-157; better for systemic tissue repair vs localised; often combined with BPC-157 in recovery protocols
- This comparison clarifies why wolverine stack optimization requires compound-specific handling. GHRP-2 and ipamorelin share the same receptor target but have different half-lives, which changes optimal dosing frequency. BPC-157 degrades faster post-reconstitution than any growth hormone secretagogue, which means vials must be used within 14–21 days rather than the standard 28-day window. TB-500's weekly dosing schedule means it doesn't interfere with daily GHRP protocols, but its systemic distribution pattern makes it unsuitable for studies requiring tissue-specific effects.